Docoh
Loading...

LJPC La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.

Company profile

Ticker
LJPC
Exchange
CEO
Larry Edwards
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
330361285

LJPC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

7 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 38.67M 38.67M 38.67M 38.67M 38.67M 38.67M
Cash burn (monthly) (positive/no burn) 3.29M (positive/no burn) 657.08K (positive/no burn) 684.42K
Cash used (since last report) n/a 9.16M n/a 1.83M n/a 1.91M
Cash remaining n/a 29.51M n/a 36.84M n/a 36.77M
Runway (months of cash) n/a 9.0 n/a 56.1 n/a 53.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 21 Michael S Hearne Common Stock Grant Aquire A No No 4.165 148 616.42 4,082
15 Jun 21 Michael S Hearne Employee Stock Option Common Stock Grant Aquire A No No 4.9 148 725.2 148
15 Jun 21 Edwards Larry G. Common Stock Grant Aquire A No No 4.165 275 1.15K 1,573
15 Jun 21 Edwards Larry G. Employee Stock Option Common Stock Grant Aquire A No No 4.9 275 1.35K 275
1 Jun 21 Tang Kevin C Common Stock Buy Aquire P Yes No 4.5277 43,734 198.01K 10,049,224
1 Jun 21 Tang Kevin C Common Stock Buy Aquire P Yes No 4.292 15,358 65.92K 10,005,490
28 May 21 Michael S Hearne Common Stock Grant Aquire A No No 3.655 169 617.69 3,934
28 May 21 Michael S Hearne Employee Stock Option Common Stock Grant Aquire A No No 4.3 169 726.7 169
28 May 21 Edwards Larry G. Common Stock Grant Aquire A No No 3.655 314 1.15K 1,298
28 May 21 Edwards Larry G. Employee Stock Option Common Stock Grant Aquire A No No 4.3 314 1.35K 314

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

74.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 74 65 +13.8%
Opened positions 15 9 +66.7%
Closed positions 6 6
Increased positions 16 19 -15.8%
Reduced positions 22 21 +4.8%
13F shares
Current Prev Q Change
Total value 98.79M 94.11M +5.0%
Total shares 20.53M 20.34M +0.9%
Total puts 55.9K 25K +123.6%
Total calls 24.4K 55.8K -56.3%
Total put/call ratio 2.3 0.4 +411.3%
Largest owners
Shares Value Change
Tang Capital Management 9.41M $39.88M 0.0%
RTW Investments 2.33M $9.87M -2.9%
BLK Blackrock 1.5M $6.36M +1.4%
Vanguard 978.85K $4.15M -6.6%
Boxer Capital 890.7K $3.78M 0.0%
D. E. Shaw & Co. 731.14K $3.1M +75.9%
MS Morgan Stanley 427.68K $1.81M +5.5%
Geode Capital Management 416.59K $1.77M +3.7%
STT State Street 395.52K $1.68M -10.4%
WFC Wells Fargo & Co. 373.76K $1.59M +1323.7%
Largest transactions
Shares Bought/sold Change
Alyeska Investment 0 -536.85K EXIT
WFC Wells Fargo & Co. 373.76K +347.5K +1323.7%
D. E. Shaw & Co. 731.14K +315.4K +75.9%
Millennium Management 175.84K +175.84K NEW
Acadian Asset Management 114.95K +114.95K NEW
Renaissance Technologies 33.6K -96.35K -74.1%
Vanguard 978.85K -69.57K -6.6%
RTW Investments 2.33M -69.48K -2.9%
First Midwest Bank Trust Division 89.34K -66.5K -42.7%
Jacobs Levy Equity Management 131.42K -61.98K -32.0%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: advertising, annum, antibacterial, arrangement, assistance, attainment, bundled, cancellable, chief, consulting, deemed, distinct, established, Europe, extent, forgiven, formulation, fully, guaranteed, inception, intrinsic, issuable, licensee, Loan, month, multiplied, National, negotiate, NMPA, nonrefundable, occurrence, oral, PAION, Paycheck, penalty, permitted, point, position, PPP, predominant, Prepaid, promissory, provision, Pte, rebate, refundable, repay, retroactive, satisfied, SBA, separate, Small, speaker, stage, sublease, submission, surveillance, Switzerland, synthetic, uncertainty, unforgiven, United, unsecured, utility, voting, Waltham, withholding
Removed: accurately, adversely, borrowing, Centre, chain, collateral, commencing, Court, disrupt, duration, effectively, escalation, extend, financed, GIAPREZATM, impacted, incremental, inducement, Initial, invested, investing, laboratory, letter, lieu, located, LP, maintain, ongoing, option, outbreak, pandemic, pledged, present, private, produce, restarted, resulted, safety, standby, supporting, therapy, Towne, travel, volatility, wholesaler